Palliative hypnosis approaches in the symptomatic treatment of amyotrophic lateral sclerosis (ALS)

被引:1
|
作者
Franklin, John E. [1 ,2 ]
机构
[1] Med Univ South Carolina, Charleston, SC USA
[2] Med Univ South Carolina, Dept Vet Affairs, Med Ctr, POB 12728, Charleston, SC 29422 USA
关键词
ALS; amyotrophic lateral sclerosis; hypnosis; palliative; SEVERE CHRONIC DISEASES; OF-LIFE; CLINICAL HYPNOSIS; DIGNITY THERAPY; ANXIETY; CARE; END; DEPRESSION; EXPERIENCE;
D O I
10.1080/00029157.2023.2252875
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Amyotrophic lateral sclerosis (ALS) is a rare, incurable, and ultimately fatal, devastating, progressive degenerative neurologic disease. It causes upheaval in the lives of patients and family caregivers alike. Palliative care can play an important supportive role in the care of patients and families dealing with the devastation of this illness. Clinical hypnosis has demonstrated benefits in treating the symptoms associated with severe chronic illness. There are, however, few studies looking at the benefits of clinical hypnosis in treating the symptom burden of ALS. This article describes palliative care and how it can provide an additional layer of support to seriously ill patients. A brief review of previous studies of hypnosis in the supportive, symptomatic treatment of ALS is provided, followed by a description of a case series of 30 Veterans who received clinical hypnosis and self-hypnosis training as a complementary treatment for the symptoms of ALS. Details of three case histories are included to highlight and discuss specific strategies and emblematic clinical responses. There is evidence that clinical hypnosis can benefit ALS patients and family caregivers struggling with this devastating illness.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] DNA hydroxymethylation in amyotrophic lateral sclerosis (ALS)
    Schaber, E.
    Appleby-Mallinder, C.
    Highley, R.
    Heath, P.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2019, 45 : 47 - 47
  • [42] Therapy options in amyotrophic lateral sclerosis (ALS)
    Dorst, J.
    Kuehnlein, P.
    Sperfeld, A. D.
    Ludolph, A. C.
    NERVENHEILKUNDE, 2007, 26 (05) : 362 - +
  • [43] NEUROFILAMENTOUS CHANGES IN AMYOTROPHIC LATERAL SCLEROSIS (ALS)
    HIRANO, A
    SASAKI, S
    DONNENFELD, H
    NAKANO, I
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1983, 42 (03): : 332 - 332
  • [44] Correlates of suffering in amyotrophic lateral sclerosis (ALS)
    Ganzini, L
    Johnston, W
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1998, 46 (09) : S10 - S10
  • [45] Motoneuron firing in amyotrophic lateral sclerosis (ALS)
    de Carvalho, Mamede
    Eisen, Andrew
    Krieger, Charles
    Swash, Michael
    FRONTIERS IN HUMAN NEUROSCIENCE, 2014, 8
  • [46] Psychiatric Aspects of Amyotrophic Lateral Sclerosis (ALS)
    Lorenzo Norris
    Guinevere Que
    Elham Bayat
    Current Psychiatry Reports, 2010, 12 : 239 - 245
  • [47] AN IMMUNOLOGICAL PROFILE OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
    MALIN, JP
    NERVENARZT, 1990, 61 (02): : 105 - 111
  • [48] Diagnosing amyotrophic lateral sclerosis (ALS) in ENT
    Harrison, L.
    Wills, A.
    Beasley, N.
    CLINICAL OTOLARYNGOLOGY, 2013, 38 (06) : 564 - 565
  • [49] Lead exposure and amyotrophic lateral sclerosis (ALS).
    Kamel, F
    Umbach, DM
    Hu, H
    Munsat, TL
    Shefner, JM
    Sandler, DP
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 1998, 147 (11) : S75 - S75
  • [50] Clinical Spectrum of Amyotrophic Lateral Sclerosis (ALS)
    Grad, Leslie I.
    Rouleau, Guy A.
    Ravits, John
    Cashman, Neil R.
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2017, 7 (08):